Pirfenidone inhalation - Avalyn Pharmaceuticals
Alternative Names: Aerodone; AP 01; GP 101Latest Information Update: 02 Dec 2024
Price :
$50 *
At a glance
- Originator Avalyn Pharma
- Class Anti-inflammatories; Antifibrotics; Heart failure therapies; Pyridones; Small molecules
- Mechanism of Action Collagen inhibitors; Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis; Interstitial lung diseases; Pulmonary fibrosis
Most Recent Events
- 19 Nov 2024 Phase-II clinical trials in Pulmonary fibrosis (Treatment-experienced) in Argentina, Australia, Canada, France, Italy, Germany, New Zealand, Poland, United Kingdom (Inhalation) (NCT06329401)
- 07 Sep 2024 Adverse event and pharmacodynamics data from the phase I/II ATLAS trial in Idiopathic pulmonary fibrosis presented at the 34th Annual Congress of the European Respiratory Society 2024 (ERS-2024)
- 20 May 2024 Efficacy and adverse events data from the phase I/II ATLAS trial in Idiopathic pulmonary fibrosis presented at the International Conference of the American Thoracic Society (ATS-2024)